These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17457998)

  • 1. An audience with... Arti Rai.
    Rai A
    Nat Rev Drug Discov; 2007 Apr; 6(4):264. PubMed ID: 17457998
    [No Abstract]   [Full Text] [Related]  

  • 2. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotech as Bush bows out.
    Lorenzo A
    Nat Biotechnol; 2008 Jan; 26(1):15-8. PubMed ID: 18183006
    [No Abstract]   [Full Text] [Related]  

  • 4. The patentability of antibodies in the United States.
    Lu DL; Collison AM; Kowalski TJ
    Nat Biotechnol; 2005 Sep; 23(9):1079-80. PubMed ID: 16151395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patent fight sparks biological warfare in the drug industry.
    Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 7. Patenting race.
    Kahn J
    Nat Biotechnol; 2006 Nov; 24(11):1349-51. PubMed ID: 17093476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating biotechnology's new fiscal opportunities.
    Purcell DJ
    Nat Biotechnol; 1998 May; 16 Suppl():51-3. PubMed ID: 9591271
    [No Abstract]   [Full Text] [Related]  

  • 9. Patent crunch pending.
    Wadman M
    Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
    [No Abstract]   [Full Text] [Related]  

  • 10. Betting on biogenerics.
    Dove A
    Nat Biotechnol; 2001 Feb; 19(2):117-20. PubMed ID: 11175723
    [No Abstract]   [Full Text] [Related]  

  • 11. Western biotechs ponder follow-on possibilities.
    Waltz E
    Nat Biotechnol; 2008 Sep; 26(9):962-3. PubMed ID: 18779793
    [No Abstract]   [Full Text] [Related]  

  • 12. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US, Brazil tangle over IP rights to drugs.
    Fox JL
    Nat Biotechnol; 2001 Aug; 19(8):698. PubMed ID: 11479544
    [No Abstract]   [Full Text] [Related]  

  • 14. Reinventing an industry.
    Mandavilli A
    Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
    [No Abstract]   [Full Text] [Related]  

  • 15. Putting your best mode forward.
    Tsao YR; Tabtiang RK
    Nat Biotechnol; 2000 Oct; 18(10):1113-4. PubMed ID: 11017054
    [No Abstract]   [Full Text] [Related]  

  • 16. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 17. US policy may encourage counterfeit drugs.
    Bouchie A
    Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME
    Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotech R&D still reeling.
    Lawrence S
    Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
    [No Abstract]   [Full Text] [Related]  

  • 20. Agbiotech issues climb US political agenda.
    Fox JL
    Nat Biotechnol; 2002 Dec; 20(12):1179-80. PubMed ID: 12454658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.